These findings suggest that a combination model of 2,3‐Sia‐PSA and 1,6‐Fuc‐PSA could effectively identify patients with high‐grade PCa and distinguish them from those with low‐grade PCa or from health controls. This evidence concerns the gene KLK3 and posterior cortical atrophy.